October 8, 2007 – Johnson & Johnson Pharmaceutical Research & Development, L.L.C., announced results from a Phase III trial that showed that investigational antibiotic ceftobiprole was found to clinically cure 86% of patients with diabetic foot infections -- including some infections that were caused by methicillin-resistant Staphylococcus aureus (MRSA)... Johnson & Johnson's Press Release -Tuesday, October 9, 2007
Johnson & Johnson Pharmaceutical R & D, Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections
October 8, 2007 – Johnson & Johnson Pharmaceutical Research & Development, L.L.C., announced results from a Phase III trial that showed that investigational antibiotic ceftobiprole was found to clinically cure 86% of patients with diabetic foot infections -- including some infections that were caused by methicillin-resistant Staphylococcus aureus (MRSA)... Johnson & Johnson's Press Release -
